<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2143">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05393388</url>
  </required_header>
  <id_info>
    <org_study_id>844403</org_study_id>
    <nct_id>NCT05393388</nct_id>
  </id_info>
  <brief_title>Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study</brief_title>
  <acronym>ABCD2-TAU</acronym>
  <official_title>Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pennsylvania Department of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will conduct a Tau PET scan in cognitively normal older adults, enrolled in the Aging&#xD;
      Brain Cohort Dedicated to Diversity Study (ABCD2-Tau) study at the University of&#xD;
      Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).Study duration&#xD;
      will generally be a one-day study visit for PET imaging, but all subjects will be followed&#xD;
      annually as part of their participation in the ABCD2 study. Findings from this study will&#xD;
      likely provide insight into the mechanisms and distinctions of age-related cognitive decline&#xD;
      and that of preclinical Alzheimer's Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2022</start_date>
  <completion_date type="Anticipated">May 2027</completion_date>
  <primary_completion_date type="Anticipated">May 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a cross-sectional study using the radiotracer 18F-Flortaucipir to determine the relationship of tau pathology to both cross-sectional and longitudinal clinical and biomarker data of ABCD2 cohort participants who are Cognitively Normal. All subjects will already be part of the longitudinal cohort study, known as the &quot;ABCD2&quot; cohort, of the PMC/ADC. For the current protocol, participants will provide informed consent before beginning any study procedures. After screening assessments, participants will undergo PET/CT scan imaging with 18F-Flortaucipir.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uptake of [18F]AV-1451 in the medial temporal lobe</measure>
    <time_frame>4 years</time_frame>
    <description>A quantitative measurement of [18F]AV-1451(standardized value uptake ratio - SUVR) within the medial temporal lobe (MTL).from PET/CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of medial temporal lobe subregion</measure>
    <time_frame>4 years</time_frame>
    <description>A quantitative measurement of volume (milimeters - mm) of medial temporal lobe (MTL) subregion from a high resolution MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thickness of medial temporal lobe subregion</measure>
    <time_frame>4 years</time_frame>
    <description>A quantitative measurement of thickness (milimeters - mm) of medial temporal lobe (MTL) subregion from a high resolution MRI.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cognitive Decline</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PET.CT using the radiotracer [18F]AV-1451</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]AV-1451</intervention_name>
    <description>[18F]AV-1451 has been developed as a positron emitting radiopharmaceutical for in vivo imaging of tau protein aggregates.</description>
    <arm_group_label>PET/CT</arm_group_label>
    <other_name>[F-18]T807</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females African Americans â‰¥ 65 years of age.&#xD;
&#xD;
          2. Part of the ABCD2 longitudinal cohort, protocol 844047, of the PMC/ADCC with consensus&#xD;
             conference designation of normal cognition.&#xD;
&#xD;
          3. ABCD2 longitudinal visit must be completed or scheduled to be completed within 180&#xD;
             days prior to the [18F]AV-1451 TAU PET scan.&#xD;
&#xD;
          4. A brain MRI must be performed within 180 days prior to their study [18F]AV-1451 TAU&#xD;
             PET scan date and be deemed of adequate quality that the scan may be used for study&#xD;
             analysis, including 3T high-resolution imaging of medial temporal lobe structures.&#xD;
&#xD;
          5. An amyloid PET scan completed or scheduled within 180 days of their study [18F]AV-1451&#xD;
&#xD;
          6. Women must be post-menopausal or surgically sterile.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have any medical or psychiatric conditions that, in the opinion of the investigator,&#xD;
             would compromise the subject's safety or successful participation in the study,&#xD;
             including major depression and prior head trauma.&#xD;
&#xD;
          2. Have evidence of structural abnormalities such as major stroke or mass on MRI that is&#xD;
             likely to interfere with analysis of the PET scan.&#xD;
&#xD;
          3. Inability to tolerate or contraindication to imaging procedures in the opinion of an&#xD;
             investigator or treating physician.&#xD;
&#xD;
          4. Have a history of significant ongoing alcohol or substance abuse or dependence based&#xD;
             on self-report.&#xD;
&#xD;
          5. Women of child bearing potential&#xD;
&#xD;
               -  The inclusion / exclusion criteria will be ascertained through self-report in&#xD;
                  conjunction with any medical history available through the participant's medical&#xD;
                  or research records (EPIC or the ADC database)*&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Wolk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David A Wolk, MD</last_name>
    <phone>215-573-7495</phone>
    <email>david.wolk@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura A Schankel</last_name>
    <email>laura.schankel@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania - Penn Memory Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David A Wolk, MD</last_name>
      <phone>215-573-7495</phone>
      <email>David.Wolk@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura A Schankel</last_name>
      <email>Laura.Schankel@pennmedicine.upenn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>May 16, 2022</study_first_submitted>
  <study_first_submitted_qc>May 23, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2022</study_first_posted>
  <last_update_submitted>November 1, 2022</last_update_submitted>
  <last_update_submitted_qc>November 1, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

